Enhancing quality evaluation in traditional Chinese medicine: Utilizing dual wavelength fusion fingerprint, electrochemical fingerprint, and DSC fingerprint.

Developing a reliable and effective quality evaluation system for traditional Chinese medicine (TCM) is both challenging and crucial for its advancement. This study employs fingerprinting techniques to establish precise and comprehensive quality control for TCM, taking Xuezhikang capsules as an example and aiming to facilitate the internationalization of TCM. The "double wavelength absorption coefficient ratio fingerprint" and "Reliability theory" are developed to determine the fingerprint peak purity and fingerprint reliability respectively. Subsequently, the dual-wavelength fusion fingerprint was obtained to avoid the limitations of a single wavelength. In addition, an electrochemical fingerprint (ECFP) was obtained to assess the similarity of electroactive components in the sample, and the Differential Scanning Calorimetry quantized fingerprint (DSC QFP) was introduced for thermal analysis. Fingerprint-efficacy correlations between PL-EC* and dual-wavelength fusion fingerprint (DWFFP) provided valuable insights that there are 76.6 % of the fingerprint compounds exhibited electroactivity. Finally, samples were classified into grades 1∼3 by combining DWFFP, ECFP and DSC QFP through the mean method, meeting the evaluation standard (SL-M > 0.9, PL-M between 80 % and 120 %). This study provides valuable information for ensuring the quality of TCM products, which represents a significant step forward in enhancing the reliability and authenticity of TCM products.

The effect of Xuezhikang capsule on gene expression profile in brown adipose tissue of obese spontaneously hypertensive rats.

ETHNOPHARMACOLOGICAL RELEVANCE: Obesity is a critical threat to global health, and brown adipose tissue (BAT) is a potential target for the treatment of obesity and comorbidities. Xuezhikang Capsule (XZK), an extract of red yeast rice, has remarkable clinical efficacy and is widely used for the treatment of hyperlipidemia and coronary heart disease. However, its modulatory effect on BAT remains unknown. AIM OF THIS STUDY: The aim of this study was to investigate the protective mechanism of XZK in the obese spontaneously hypertensive rat (SHR) model by evaluating the regulatory effect of XZK on the BAT gene profile through transcriptome sequencing. MATERIALS AND METHODS: The SHRs were randomly divided into four groups: the standard chow diet (STD) group, the STD supplemented with 126 mg/kg of XZK group, the high-fat diet (HFD) group, and the HFD supplemented with 126 mg/kg of XZK group. All SHRs were fed for 18 weeks. The metabolic phenotypes, including body weight, fat mass, oral glucose tolerance test (OGTT), and serum glucose and lipid levels, was evaluated, and hematoxylin and eosin staining (H&E) staining was performed to evaluate the adipose tissue histopathological phenotype. Transcriptome sequencing was performed to determine the mechanism by which XZK improves the metabolic phenotype and the expression of key differential expression genes was verified by real-time quantitative polymerase chain reaction (qRT-PCR). RESULTS: XZK inhibited HFD-induced weight gain and adipose tissue remodeling in SHRs and prevented hypertrophy of epididymal adipocytes and maintained the brown fat phenotype. XZK intervention also improved glucose and lipid metabolism in SHRs, as suggested by a reduction in serum triglyceride (TG), low-density cholesterol (LDL-C), and fasting blood glucose (FBG) levels as well as increasing in serum high-density cholesterol (HDL-C) levels. Transcriptome sequencing analysis confirmed the regulatory effect of XZK on the gene expression profile of BAT, and the expression patterns of 45 genes were reversed by the XZK intervention. Additionally, the results of the transcriptome analysis of 10 genes that are important for brown fat function were in line with the results of qRT-PCR. CONCLUSIONS: XZK protected SHRs from HFD-induced obesity, inhibited fat accumulation and improved glucolipid metabolism. Additionally, the protective effect of XZK on the overall metabolism of obese SHRs might partly be related to its regulatory effect on the BAT gene expression profile. These findings might provide novel therapeutic strategies for obesity-related metabolic diseases in traditional Chinese medicine (TCM).

Rapid identification of chemical constituents in Xuezhikang Capsule by UPLC-Q-TOF/MSE combined with the establishment of UNIFI MS database / 药学学报

An UPLC-Q-TOF/MSE technology coupled with UNIFI database was used to develop a rapid, high coverage, accurate and efficient chemical composition qualitative method for Xuezhikang Capsule. A UNIFI database was established utilizing compound name, formula, structure, following automatic matching with high-resolution mass numbers, isotope distributions, mass deviations, fragment ion matching, and chromatographic retention features in UNIFI database to achieve the qualitative results of natural products in Xuezhikang Capsules. Combined with manual confirmation, 82 chemical components were identified in Xuezhikang Capsules, and the MS2 fragmentation pathway of typical organic acids, flavonoids, monacrines, and monascus were analyzed to ensure accuracy of the LC-MS workflow. This study clarified the chemical substance basis of Xuezhikang Capsules by LC-MS technology, providing experimental data support for the identification of key quality attributes, quality control and consistency evaluation in the manufacturing process of Xuezhikang Capsules.

Randomized Double-blind Clinical Trial on Efficacy of Xuezhikang Capsule on Hyperuricacidemia and its Safety / 中国中医药信息杂志

Objective To assess the efficacy of Xuezhikang capsule on hyperuricacidemia and its safety. Methods The study was designed as a random, double-blind placebo controlled clinical trial. 80 hyperuricacidemia patients were divided randomly into test group and control group (40 in test group and 40 in control group). The course of treatment was 28 days. Results 75 patients finished the trial (38 in test group and 37 in control group). After 28 days of treatment, the differences in reduction of UA, XOD, FINs, Homa-IR, TC, TG, Lp, CRP, ET, ?2-MG and elevation of HDL of the test group were statistic significance. No side effect was found in the trial. Conclusion Xuezhikang capsule has good clinical effect and safety in the treatment of hyperuricacidemia.

Efficacy of Xuezhikang Capsule for hyperlipemia in young adult patients / 医学研究生学报

Objective: The purpose of this study was to further investigate other effects of Xuezhikang Capsule than blood lipid decreasing,particularly its effect on the high sensitivity C reactive protein(Hs-CRP) in young adult patients with hyperlipemia.Methods: We treated 135 hyperlipemia patients aged 18-39 years with Xuezhikang Capsule at 0.6g tid for 8 successive weeks,followed by detection of the levels of serum Hs-CRP and blood lipid.Results: After Xuezhikang treatment,the level of serum Hs-CRP was significantly decreased in the young adult patients with hyperlipemia(P

Clinical Observation on Xuezhikang Capsule for 116 Cases of Coronary Heart Disease with Abnormal Blood Lipid / 中医杂志

Objective To observe the different effect of Xuezhikang Capsule on the patients of coronary heart disease (CHD) with abnormal blood lipid in different syndromes.Methods Of the 116 patients of CHD with abnormal blood lipid diagnosed by coronary arteriography and blood test, 30 were blood stasis syndrome, 23 phlegm turbid syndrome, 26 phlegm retention syndrome, and 37 non-phlegm non-stasis syndrome. Based on the standard treatment with modern medicine, Xuezhikang Capsule was given 0.6g each time, twice a day, for 24 weeks in succession.Results After the treatment, total cholesterol (TC), triglyceride (TG) and low density lipoprotein-C (LDL-C) were decreased (P

Treating non-alcoholic fatty liver disease accompanied by hyperlipidemia with Xuezhikang Capsule / 中成药

AIM: To study the curative effect of Xuezhikang Capsule on non-alcoholic fatty liver disease accompanied by hyperlipidemia. METHODS: Small dosage of Xuezhikang Capsules had been administrated to the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia for 6 months. 32 healthy people had been chosen as control group at the same time. At the time points of before and after curing, body weight index. Type B ultrasonic, liver function, serum lipids, serum glucose and insulin levels had been tested. The McAuley index and the insulin resistance index of the homeostasis model assessment had been taken to evaluate insulin resistance. Liver biopsy had been conducted in some of the patients to compare the tissue changes before and after curing. RESULTS: After being treated with Xuezhikang Capsule, levels of insulin resistance serum lipids and ALT/AST in the patients with non-alcoliolic fatty liver disease had gone downward markedly. The histological observation in some of the patients had improved. No toxicity had been found. CONCLUSION: It is safe and potent to take the small dosage of Xuezhikang Capsule to cure the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia.